PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8... Read More

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m.... Read More

PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company’s Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA). Data from the pilot study demonstrated that an oximeter embedded in a precision medical device can accurately, safely,... Read More

PLEASANTON, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it will report its fourth quarter and fiscal year 2023 financial results and provide a business update before market open on Monday, March 18, 2024 at the 36 th Annual ROTH Conference and via a live webcast. ProSomnus Chief Executive... Read More

PLEASANTON, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today that the United States Food and Drug Administration (the “FDA”) has accepted, and is in the process of reviewing, the Company’s premarket notification for its ProSomnus® EVO® precision medical device for the treatment of patients with severe... Read More

PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-positioned to support patients with OSA and sleep physicians who can no longer access discontinued OSA devices. Earlier in January, Philips Respironics announced the discontinuation of many devices used for the treatment and... Read More

PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of UnitedHealthcare’s updated medical policy (#2024T0525NN) for Obstructive and Central Sleep Apnea, effective March 1, 2024. The updated policy will establish oral appliance therapy (OAT), such as ProSomnus’s Precision OAT devices, as... Read More

PLEASANTON, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, today announced the publication of a study by the Cureus Journal of Medical Science , in which the Company’s precision oral appliance therapy (OAT) devices successfully treated patients’ OSA. “The study underscored what we see daily in our practice at Star Sleep &... Read More

PLEASANTON, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the leading non-CPAP Obstructive Sleep Apnea Therapy, today announced financial results for the third quarter ended September 30, 2023. Recent Business Highlights Generated record revenues of $7.1 million in the quarter, representing an increase of 41.5% year-over-year compared to the third quarter of 2022, and $19.8 million... Read More

PLEASANTON, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its third quarter financial results after market close on Thursday, November 9, 2023. ProSomnus Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow, will host a conference call at 1:30 pm PT / 4:30 pm ET. Investor Call Dial-In... Read More

PLEASANTON, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announces management’s participation in the 2023 Roth Capital Healthcare Opportunities Conference at the Yale Club in New York City on October 12, 2023. ProSomnus’ Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow,... Read More

PLEASANTON, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced the completion of a $10 million convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital, LLC. ProSomnus’s Executive Chair, Chief Executive Officer, and Chief Financial Officer are... Read More

PLEASANTON, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced that their precision sleep apnea devices will be prominently featured in the scientific programs at upcoming medical conferences. The new scientific abstracts and podium presentations feature new data and additional data reporting on the... Read More

Precision oral appliance therapy effective among 90% of moderate and 85% of severe OSA patients In an Intent-to-Treat analysis, precision OAT demonstrated twice the mean disease alleviation as CPAP Results for treating Severe OSA patients with precision oral appliance therapy establish rationale for head-to-head clinical trial with hypoglossal nerve stimulation PLEASANTON, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ProSomnus,... Read More

PLEASANTON, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company” or “ProSomnus”) (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced financial results for the second quarter ended June 30, 2023. Recent Business Highlights Generated record quarterly revenues of $6.9 million in the second quarter of 2023, and $12.7 million in the first half of... Read More

PLEASANTON, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), announced plans to design a head-to-head clinical trial comparing its precision oral appliance therapy (OAT) and hypoglossal nerve stimulation (HNS) in treating patients with severe OSA. The clinical trial plans follow updated results from the First Line... Read More

PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its strong second quarter financial results prior to market open on Thursday, August 3, 2023. ProSomnus Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow, will host a conference call at 5:30 am PT / 8:30 am ET. Management... Read More

PLEASANTON, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), announced the results of a survey conducted in partnership with Prodege , a cutting-edge consumer marketing and insights platform, on the major obstacles to identifying and treating snoring and OSA, including a lack of awareness of where to seek medical advice.... Read More

PLEASANTON, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), announced the presentation of three abstracts at the 2023 SLEEP Annual Meeting, hosted jointly by the Associated Professional Sleep Societies, LLC (APSS), the American Academy of Sleep Medicine (AASM), and the Sleep Research Society (SRS), held June 3-7 in... Read More

PLEASANTON, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), announced the presentation of four abstracts at the 2023 American Academy of Dental Sleep Medicine (AADSM) Annual Meeting, held May 19-21 in Philadelphia, Pennsylvania, and two abstracts at the American Thoracic Society (ATS) 2023 International... Read More

PLEASANTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company” or “ProSomnus”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the first quarter ended March 31, 2023. Recent Business Highlights Generated year-over year revenue growth of 55% reflecting revenues of $5.8 million for the first quarter compared to... Read More

PLEASANTON, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), will report its first quarter financial results after market close on Thursday, May 9, 2023. ProSomnus Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow, will host a conference call that day at 1:30 p.m. PT /... Read More

PLEASANTON, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the results of a retrospective study demonstrating the efficacy of Precision Oral Appliance Therapy (OAT) compared to Traditional OAT for the treatment of OSA. The study indicates that precision oral appliances by... Read More

PLEASANTON, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the publication of four abstracts in the Journal of Dental Sleep Medicine . The abstracts can be found at https://aadsm.org/journal/abstracts_issue_102.php . These data will be presented in oral and poster presentations... Read More

PLEASANTON, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent serial number (USPN) 11,617,677 on April 4, 2023, an addition to a portfolio of several issued U.S. patents covering the Company’s iterative titration... Read More

PLEASANTON, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and fiscal year ended December 31, 2022. Recent Business Highlights Generated revenues of $5.8 million for the fourth quarter and $19.4 million for the fiscal year 2022, an... Read More

PLEASANTON, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that the U.S. Patent and Trademark Office (USPTO) has allowed a patent application covering the Company’s proprietary automated manufacturing process for the Company’s precision medical devices; this is the third patent... Read More

PLEASANTON, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), will report its fourth quarter and full year 2022 financial results after market close on Thursday, March 30, 2023. ProSomnus Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow, will host a conference call... Read More

PLEASANTON, Calif., March 10, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that an abstract showcasing data from a study comparing the efficacy of Precision Oral Appliance Therapy (OAT) and traditional OAT has been accepted for a Thematic Poster Session at the European Respiratory Society... Read More

SAN FRANCISCO, March 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA ), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announces that Company management will participate in two investor conferences in the month of March 2023: 35 th Annual Roth Conference on March 12-14, 2023 33 rd Annual Oppenheimer Healthcare Conference on March 13-15, 2023 About 35... Read More

PLEASANTON, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the appointment of Brian Dow as Chief Financial Officer, effective March 1, 2023. Mr. Dow brings more than 28 years of experience advancing privately-held and publicly-traded life science companies with expertise... Read More

SAN FRANCISCO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced certain unaudited results for the quarter and full year ended December 31, 2022. Preliminary 2022 Revenue Guidance and Recent Business Highlights Revenue for the full year 2022 is expected to increase over 35% year-over-year... Read More

SAN FRANCISCO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that an abstract showcasing data from the First Line Obstructive Sleep Apnea Treatment study (FLOSAT) has been accepted for an oral presentation at the American Thoracic Society (ATS) 2023 International Conference , being... Read More

First prospective crossover study comparing the effectiveness of precision oral appliance therapy as front-line therapy relative to CPAP for the treatment of obstructive sleep apnea ProSomnus precision intraoral medical devices exclusively utilized for the precision oral appliance therapy arm of the study SAN FRANCISCO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision... Read More

SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the enrollment of the first patient in its Severe Obstructive Sleep Apnea (SOS) study. The SOS study is a prospective, FDA-reviewed, multi-center, single-arm study evaluating the safety and efficacy of precision oral... Read More

SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision oral appliance therapy (OAT) for the treatment of Obstructive Sleep Apnea (OSA), today announced that its ProSomnus EVO® [PH] Sleep and Snore Device now qualifies for Medicare reimbursement. The Pricing, Data Analysis, and Coding (PDAC) Contractor has reviewed and verified the device for the Healthcare... Read More

Treatment with Precision Oral Appliance Therapy Demonstrated Significant Improvements in Apnea-Hypopnea Events, Respiratory Disturbances, Oxygen Saturation, REM Sleep, Sleep Efficiency and Sleepiness 79.6% Reduction in Sleep Apnea Events with Precision Oral Appliance Therapy Relative to Baseline Testing ProSomnus Precision Intraoral Medical Devices Exclusively Utilized in this Independent Study SAN FRANCISCO, Dec. 08, 2022... Read More

Completes business combination with Lakeshore Acquisition I Corp. ProSomnus common stock will trade on Nasdaq Capital Market under ticker symbol “ OSA ” SAN FRANCISCO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the completion of its previously announced business combination with Lakeshore... Read More